Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Otte, Katharina, Zhao, Kai, Braun, Madita, Neubauer, Andreas, Raifer, Hartmann, Helmprobst, Frederik, Barrera, Felipe Ovalle, Nimsky, Christopher, Bartsch, Jörg W., Rusch, Tillmann
Formatua: Artikulua
Hizkuntza:ingelesa
Argitaratua: Philipps-Universität Marburg 2022
Gaiak:
Sarrera elektronikoa:PDF testu osoa
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!